TUNICRIS-julkaisut - Trepo

Viitteet 1-1 / 1

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer : A Secondary Analysis of the SOLD Randomized Clinical Trial

Joensuu, Heikki; Fraser, Judith; Wildiers, Hans; Huovinen, Riikka; Auvinen, Päivi; Utriainen, Meri; Villman, Kenneth K.; Halonen, Päivi; Granstam-Björneklett, Helena; Tanner, Minna; Sailas, Liisa; Turpeenniemi-Hujanen, Taina; Yachnin, Jeffrey; Huttunen, Teppo; Neven, Patrick; Canney, Peter; Harvey, Vernon J.; Kellokumpu-Lehtinen, Pirkko Liisa; Lindman, Henrik (08 / 2024)
article

Importance: The standard adjuvant treatment for patients with ERRB2-positive breast cancer is chemotherapy plus 1 year of trastuzumab. Shorter durations of trastuzumab administration improve cardiac safety, but more ...